Skip to main content
European Commission logo print header

New anti-inflammatory natural products from medicinal plants using inducible transcription factors and their signalling pathways as molecular targets

Objetivo

The consortium assembled here will contribute to the development of new anti-inflammatory drugs for clinical use in the European Union and beyond by identifying medicinal plant extracts with NF-kappa inhibitory activity and/or inhibitory effects on targets of the inflammatory cascade in peripheral and CNStissues. These targets will include, for example, IL-1beta, TNFalpha, PGE2, and IL-6. Subsequently the compounds mediating this inhibitory effect will be isolated and their structure elucidated. The consortium has the capacity to evaluate the extracts in a large set of targets related to the transcriptional activation of gene products of relevance for inflammatory, immunomodulatory and apoptotic activity. Select compounds will be further studied in in-vivo as well as in-Microsystems and we expect that this research will form the basis for preclinical and clinical development.

Convocatoria de propuestas

Data not available

Régimen de financiación

CSC - Cost-sharing contracts

Coordinador

UNIVERSITY OF LONDON
Aportación de la UE
Sin datos
Dirección
MALET STREET, SENATE HOUSE
WC1E7HU LONDON
Reino Unido

Ver en el mapa

Coste total
Sin datos

Participantes (7)